Publication

The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck

Journal Paper/Review - Dec 12, 2013

Units
PubMed
Doi

Citation
Kupferman M, Takes R, Stöckli S, Rinaldo A, Medina J, Devaney K, Civantos F, Bradford C, Kubik M, Ferlito A. The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck. Am J Otolaryngol 2013; 35:226-32.
Type
Journal Paper/Review (English)
Journal
Am J Otolaryngol 2013; 35
Publication Date
Dec 12, 2013
Issn Electronic
1532-818X
Pages
226-32
Brief description/objective

From 18% to 35% of cutaneous melanomas are located in the head and neck, and nearly 70% are thin (Breslow thickness ≤ 1 mm). Sentinel lymph node biopsy (SLNB) has an established role in staging of intermediate-thickness melanomas, however its use in thin melanomas remains controversial. In this article, we review the literature regarding risk factors for occult nodal metastasis in thin cutaneous melanoma of the head and neck (CMHN). Based on the current literature, we recommend SLNB for all lesions with Breslow thickness ≥ 0.75 mm, particularly when accompanied by adverse features including mitotic rate ≥ 1 per mm(2), ulceration, and extensive regression. SLNB should also be strongly considered in younger patients (e.g. < 40 years old), especially in the presence of additional adverse features. All patients who do not proceed with sentinel lymph node biopsy must be carefully followed to monitor for regional relapse.